SML3914

Cabozantinib

≥98% (HPLC)

• 別名: BMS 907351, BMS-907351, BMS907351, N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane1,1-dicarboxamide, N-(4-{[6,7-bis(Methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, XL 184, XL-184, XL184
• 実験式（ヒル表記法）: C₂₈H₂₄FN₃O₅
• CAS番号: 849217-68-1
• 分子量: 501.51
• MDL番号: MFCD20926324
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear
• 保管温度: -10 to -25°C
• SMILES記法: Fc1ccc(cc1)NC(=O)C5(CC5)C(=O)Nc2ccc(cc2)Oc3c4c(ncc3)cc(c(c4)OC)OC
• InChI: 1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)

詳細

生物化学的／生理学的作用

Cabozantinib (XL184; BMS‐907351) is an orally active, potent inhibitor against multiple receptor tyrosine kinases, notably VEGFR2/KDR (IC50 = 35 pM), MET (IC50 = 1.3 nM/wt, 3.8 nM/Y1248H, 11.8 nM/D1246N, 14.6 nM/K1262R), KIT, RET, AXL, TIE2, and FLT3 (IC50 = 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib inhibits MET-driven proliferation in cancer cultures (IC50 = 9.9 nM/Hs746T, 19 nM/SNU-5) and simultaneously suppressing metastasis, angiogenesis and tumor growth in vivo (3-100 mg/kg via single or daily p.o. to mice with human MDA-MB-231 xenograft, 1-60 mg/kg via single or daily p.o. to rats with C6 rat glioma).

安全性情報

• ピクトグラム: GHS08,GHS07
• シグナルワード: Danger
• 危険有害性情報: H302,H360FD,H373
• 注意書き: P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313
• 危険有害性の分類: Acute Tox. 4 Oral - Repr. 1B - STOT RE 2
• ターゲットの組織: Bone marrow,Kidney,Endocrine system,Gastrointestinal tract,Liver
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable